Pyxis Oncology (PYXS) Depreciation & Amortization (CF) (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q4 2025.

• On a quarterly basis, Depreciation & Amortization (CF) rose 426.73% year-over-year to $2.9 million in Q4 2025; TTM through Dec 2025 was $4.5 million, a 51.27% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, up 51.27% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $2.9 million, up from $527000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for PYXS reached as high as $2.9 million in Q4 2025 and fell as low as $113000.0 in Q1 2021.
• Historically, Depreciation & Amortization (CF) has averaged $538800.0 across 5 years, with a median of $523500.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) soared 487.37% in 2024 and sank 50.54% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $158000.0 in 2021, then gained by 21.52% to $192000.0 in 2022, then jumped by 259.38% to $690000.0 in 2023, then declined by 20.29% to $550000.0 in 2024, then soared by 426.73% to $2.9 million in 2025.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.9 million in Q4 2025, $527000.0 in Q3 2025, and $535000.0 in Q2 2025.